The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
C-reactive protein (CRP) is an acute-phase protein that is produced in large amounts by hepatocytes, upon stimulation by the cytokines interleukin-6, tumor-necrosis-factor-alpha and interleukin-1beta, during an acute-phase response. CRP is an objective marker of inflammation and, in gastrointestinal diseases such as Crohn's disease and acute pancreatitis, its levels correlate well with clinical disease activity. In contrast to its use as a marker in Crohn's disease, however, CRP is a less reliable marker of inflammation and disease activity in patients with ulcerative colitis, except perhaps for severe, extensive colitis. The increased production of CRP after an acute-phase stimulus, such as active gut inflammation, might explain why strong anti-inflammatory agents, such as anti-tumor-necrosis-factor-alpha antibodies and other biologic agents, work particularly well in patients with increased levels of CRP. CRP is also useful as a laboratory marker to predict prognosis and relapse in patients with Crohn's disease and acute pancreatitis. Elevated CRP levels have been associated with an increased risk of colorectal cancer and are a marker of poor prognosis, indicating more advanced disease and, possibly, reduced survival. An important question that remains is how often CRP levels should be measured. Until there are more data, the use of CRP and of other biomarkers should be seen as an additional tool that aids clinical observation and physical examination, but that cannot repla…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CRP level is often used in chronic inflammatory diseases as a marker of active inflammation; it is typically understood to be an acute phase reactant 19 .”
From The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity (2009) · cites this paper as [19]
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationDanesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953 · cited 1×
“68), it was less strong as a risk factor compared with well-established risk factors, such as increased cholesterol and cigarette smoking”
BackgroundInfliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752 · cited 1×
“The anti-TNFα antibodies are very efficacious in patients with Crohn's disease”
BackgroundSelf-citationThe Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526 · cited 1×
“Further evidence that inflammation is important in tumorigenesis is provided by the ability of anti-inflammatory drugs to reduce polyp formation and colorectal cancer risk”
BackgroundInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226 · cited 1×
“The anti-TNFα antibodies are very efficacious in patients with Crohn's disease”
BackgroundSelf-citationTreatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis
Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., & Offerhaus, G. J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281805 · Cited by 1,717 · cited 1×
“Further evidence that inflammation is important in tumorigenesis is provided by the ability of anti-inflammatory drugs to reduce polyp formation and colorectal cancer risk”
BackgroundA Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416 · cited 1×
“Further evidence that inflammation is important in tumorigenesis is provided by the ability of anti-inflammatory drugs to reduce polyp formation and colorectal cancer risk”
BackgroundPredicting outcome in severe ulcerative colitis.
Travis, S. P., Farrant, J. M., Ricketts, C., Nolan, D. J., Mortensen, N. M., Kettlewell, M. G., & Jewell, D. P. (1996) · Gut · doi:10.1136/gut.38.6.905 · Cited by 788
Vigushin, D. M., Pepys, M. B., & Hawkins, P. N. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116336 · Cited by 636 · cited 1×
“infection, inflammation, trauma, childbirth, severe burns, stress and neoplasia), however, the liver has a large capacity to increase the baseline production of CRP by upregulating its transcription in hepatocytes”
Background
Research works printed but not linked: 1
- Rutgeerts P et al. (2003) Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn's disease [Abstract]. Gut 52 (Suppl): A239
Cited by
Items 101–151 of 151
Kathamuthu, G. R., Bhavani, P. K., Singh, M., Saini, J. K., Aggarwal, A. N., Ansari, M. S. S., Garg, R., & Babu, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.896551 · Cited by 5
C-REACTIVE PROTEIN LEVELS IN ACUTE PANCREATITIS AND ITS PROGNOSTIC SIGNIFICANCE
Joshi, M. A., Joshi, A. A., Gokhale, A. V., Manay, P., Gadhire, M., & Singh, M. (2013) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/1629 · Cited by 5
Natakusuma, T. I. S. D., Mahadewa, T. G. B., Mardhika, P. E., Maliawan, S., Senapathi, T. G. A., & Ryalino, C. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.6985 · Cited by 5
“CRP synthesis is induced mainly by IL-6 and increased by IL-1β and TNF-α [100], [101].”
BackgroundLuo, X., Cai, B., & Jin, W. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03395-5 · Cited by 5
García-Nicolás, M., Pérez-Álvarez, M. C., Abellán-Alfocea, F., Arroyo‐Manzanares, N., Campillo, N., Val, B. D., Jiménez‐Santos, E., Zarauz-García, J., Sáenz, L., & Viñas, P. (2023) · Chemosensors · doi:10.3390/chemosensors11020139 · Cited by 4
Multiple Faces of C-Reactive Protein: Structure–Function Relationships
Ansar, W. (2020) · Springer eBooks · doi:10.1007/978-981-15-6787-2_1 · Cited by 4
Stress-related genetic factors modify the effect of socioeconomic status on cardiovascular risk
Karam, K. A., Abohashem, S., Lau, H. C., Civieri, G., Aldosoky, W., Khalil, M., Arora, G. S., Rollings, R. C., Assefa, A., Ahmad, T. Z., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02130-2 · Cited by 3
Clinical spectrum of intra-abdominal abscesses in patients admitted to the emergency department
Kim, K., Kim, E., & Lee, J. H. (2020) · Australasian Emergency Care · doi:10.1016/j.auec.2019.12.009 · Cited by 3
Evaluation of therapeutic efficacy of medicinal herbal mixture in sheep ruminal acidosis
Elnady, H., Ghanem, M. M., Attar, H. E. E., Abdel-Raoof, Y., Hefnawy, A., & Elkhaiat, H. M. (2019) · Benha Veterinary Medical Journal · doi:10.21608/bvmj.2019.17565.1103 · Cited by 3
“When the inflammation or tissue destruction is resolved, CRP levels fall, making it a useful marker for monitoring disease activity Vermeire et al. (2005).”
BackgroundC-Reactive Protein in Inflammatory Bowel Disease
Malakar, S. (2020) · Springer eBooks · doi:10.1007/978-981-15-6787-2_3 · Cited by 3
Faecal biomarkers of gastrointestinal functionality in animals
Rathod, A. K., & Dhok, A. P. (2024) · Journal of Animal and Feed Sciences · doi:10.22358/jafs/175759/2024 · Cited by 3
“As a result, its presence in faeces implies neutrophil migration to the intestinal tract and its infiltration (Vermeire et al., 2004; 2005).”
BackgroundMicroglial Response to Inflammatory Stimuli-Impact of Protein Acetylation and Phosphorylation
Huuskonen, J. (2007) · Cited by 4
Sumalai, T., Wutthiwitthayaphong, S., Ruenphet, S., & Suwannachote, T. (2025) · Veterinary Sciences · doi:10.3390/vetsci12121158 · Cited by 2
Limsrivilai, J., Yodmalai, C., Chaemsupaphan, T., Sattayalertyanyong, O., Subdee, N., Permpim, P., Phaophu, P., Kaosombatwattana, U., Pausawasdi, N., Riansuwan, W., et al. (2024) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000747 · Cited by 2
“Furthermore, a connection between CRP levels and both cancer incidence and mortality has been identi fi ed in some studies (5 – 7).”
BackgroundIde, Y., Furusawa, Y., Sogawa, T., Takahashi, K., Kuramoto, T., Noguchi, A., Takahashi, M., & Miura, N. (2025) · Veterinary Sciences · doi:10.3390/vetsci12040356 · Cited by 2
Clinical Features and Diagnosis of Crohn's Disease
Ananthakrishnan, A. N., Xavier, R. J., & Podolsky, D. K. (2017) · Inflammatory Bowel Diseases · doi:10.1002/9781119077633.ch2 · Cited by 2
Correlation between PAI-1, leptin and ferritin with HOMA in HIV/AIDS patients
Dragović, G., Šumarac-Dumanović, M., Al-Musalhi, K., Soldatović, I., Andjić, M., Jevtović, D., & Nair, D. R. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.06.004 · Cited by 2
Kamr, A. M., Hassan, H. Y., Aly, M., Nayel, M., Elsify, A. M., & Salama, A. A. (2017) · Kufa Journal For Veterinary Medical Sciences · doi:10.36326/kjvs/2017/v8i24102 · Cited by 2
Mostafa, T. M., Ibrahim, O. M. H., Badra, G., & El-Berri, E. I. A. E.-K. (2015) · American Journal of Biomedical Sciences · doi:10.5099/aj150300176 · Cited by 2
“In addition, hepatocytes produce CRP in large amounts upon stimulation by the cytokines like IL-6 and TNF-α during the acute-phase response [24].”
BackgroundAltered distribution of tissue galectins correlates with mucosal dysregulation in SIV infection
Premeaux, T. A., Yeung, S. T., Johnson, S. D., Moar, P., Byrareddy, S. N., & Ndhlovu, L. C. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf200 · Cited by 1
“…the NHP model further confirm this relationship, demonstrating that elevated levels of CRP and sCD14, both of which are also elevated in IBDs 51,52 are associated with decreased tight junction expression, thereby strengthening the link between inflammation and compromised intestinal barrier…”
Chen, B. C., Mertens, A., Lin, C.-H., Tan, S. T., Jamshed, F., Figueroa, D., Hemlock, C., Butzin-Dozier, Z., Fernald, L. C. H., Stewart, C. P., et al. (2025) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2025.107596 · Cited by 1
Lam, C. S., O'Connell, K., Monroy‐Iglesias, M. J., Du, M., Romano, M. E., Giovannucci, E. L., Mao, J. J. J., & Kantor, E. D. (2026) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70484 · Cited by 1
“C-reactive protein (CRP) is an acute-phase protein produced in response to inflammation and commonly used as an marker in inflammatory bowel disease (IBD) [ 25 ].”
Mousavi, S. R., Talebianfar, M., Zeinalzadeh, M., Saberi, A., Kaviani, A., Aminseresht, M., & Heidari, A. (2008) · Iranian Journal of Cancer Prevention · Cited by 1
Ali, A. M., Abed, H. H., Nayif, E. M., & Salman, H. A. (2024) · Siberian Journal of Life Sciences and Agriculture · doi:10.12731/2658-6649-2024-16-2-708 · Cited by 1
“There is a high correlation between inflammation and some disorder disease and strong C-reactive protein response including Crohn’s disease and rheumatoid arthritis [27; 28].”
BackgroundMolecular Profiling of IBD Subtypes and Therapy Responses
Lee, H., & Cleynen, I. (2019) · Springer eBooks · doi:10.1007/978-3-030-28703-0_8 · Cited by 1
Inflammatory Processes and Risk of Cancer: Epidemiological Research
Prizment, A. E. (2010) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
Ding, X., Zha, Q., & Lü, A. (2009) · International Conference on Bioinformatics and Biomedical Engineering · doi:10.1109/icbbe.2009.5163368 · Cited by 1
“Some researches have indicated that IgG, Tumor Necrosis Factor-alpha and C-Reaction Protein play the vital roles in the pathogenesis of RA and UC, and could be taken as the biologic markers as indicators of disease progression and remission in RA and UC [10-11].”
BackgroundC-reactive protein, periodontitis and systemic inflammation.
Megson, E. (2011) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · Cited by 1
Fecal calprotectin in children with special reference to inflammatory bowel disease
Fagerberg, U. L. (2007) · Figshare
Rectocolite hémorragique: épidémiologie et diagnostic
Uzzan, M., & Tréton, X. (2013) · Côlon & Rectum · doi:10.1007/s11725-013-0435-5
Can Octreotide Prevent Post-ERCP Pancreatitis?
Kaya, E. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01327.x
How do you judge relapse in Crohnʼs disease?
Vatn, M. H. (2008) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200810001-00119
Novel biomarkers in vascular remodelling and inflammation in pulmonary arterial hypertension
Gurung, R. (2016) · UCL Discovery (University College London)
Crohn’s disease activity evaluation based on imaging studies and biomarkers
Piotrowicz, G., Klufczyńska, A., Kowerzanow, J., Piotr Banaszkiewicz, & Rydzewska, G. M. (2018) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2018.09.00292
The Role of Biomarkers in Treatment Algorithms for Ulcerative Colitis ( UC )
Khanna, R., & Feagan, B. G. (2019) · Wiley eBooks · doi:10.1002/9781119289234.ch2
Interplay between inflammatory process and platelet activation in chronic spontaneous urticariaPreprint
Wang, L., & Lu, Z. (2020) · doi:10.22541/au.159188589.98513792
Bathe, A. L. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8437
Famularo, G., & Minisola, G. (2010) · Springer eBooks · doi:10.1007/978-88-470-1472-5_7
Correlation of MLR with CRP and MPVPCR with LED in Traumatic Brain Injury
Natakusuma, T. I. S. D., Mahadewa, T. G. B., Maliawan, S., Budayanti, N. N. S., Senapathi, T. G. A., & Muliarta, I. M. (2023) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2023.11299
Evaluating the Levels of Calprotectin in Patients with Chronic Non-specific Colitis: A Brief ReportPreprint
Rafiei, R., Khodabakhsh, A. N., Rafiei, F., Kamyab, A., Ebrahimi, A., & Ashkani‐Esfahani, S. (2023) · medRxiv · doi:10.1101/2023.04.08.23288148
“Fecal markers such as calprotectin and lactoferrin, have higher 15 specificity for the diagnosis of GI diseases in comparison with serological markers [7-11].”
BackgroundMethodShort-term muscle loss after gastrointestinal cancer surgery: A two-phase study
Xu, X. (2024) · Queensland University of Technology · doi:10.5204/thesis.eprints.250840
The Role of C - Reactive protein in Inflammatory Diseases: Insights from a Mini-Review
Wangsu, T., & Phukan, J. K. (2024) · Journal of biochemistry. · doi:10.52338/job.2024.4066
Nutritional and functional roles of an endo-1,4-β-D-mannanase in young tom turkeys
Aderibigbe, A. S., Dridi, S., Baxter, M., Sokale, A. O., Fickler, A., & von Heimendahl, E. (2025) · Poultry Science · doi:10.1016/j.psj.2025.105948
“The CRP is a well-known marker of inflammation produced mainly in the liver but to a minor extent in intestinal tissues (Vermeire et al., 2005), and its downregulation in the present study indicates low or inactive inflammatory processes.”
Hazard assessment of engineered nanomaterials : impacts on hepatic and renal models
Kermanizadeh, A. (2013)
Molecular Profiling of IBD Subtypes/Response to Therapy
Cleynen, I., & Vermeire, S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8256-7_8
Self-citationMahmoud, M. A., Buiatte, V., Baumrucker, C. R., Bryan, D. D. S. L., Proszkowiec‐Weglarz, M., Miska, K. B., Jenkins, M. C., Chadwick, C. C., & Lorenzoni, A. G. (2025) · Avian Diseases · doi:10.1637/aviandiseases-d-24-00096
Shamohammadi, M., Arianezhad, E., Yarahmadi, D., Ullah, S. E., Teymoori, M. H., Shams, Z., Nikkhah, A., Tizmaghz, A., & Zarghami, S. Y. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01603-x · Cited by 1
“Elevated CRP reflects systemic inflammation while low albumin indicates malnutrition [13 , 14].”
Lwere, K., Nakasujja, N., Muwonge, H., Sendagire, H., Gumikiriza‐Onoria, J. L., Buwembo, D., Buwembo, W., Kabwigu, S., Mukasa, J. K., Kirya, F., et al. (2026) · Medicine · doi:10.1097/md.0000000000050956
Pro-Inflammatory and Diagnostic Roles of Serum Amyloid A and C-reactive protein in Schizophrenia
Atere, A. D., Ajani, O. F., Joseph, G. U., & Abdullah, M. H. (2023) · African Journal of Biomedical Research · doi:10.4314/ajbr.v26i1.4 · Cited by 1
“CRP is an acute-phase protein (APP) produced in large amounts by hepatocytes in response to interleukin-6 (IL-6) stimulation during an acute-phase response, which is scientifically reasonable (Vermeire et al ., 2005; Overgaard et al ., 2013).”
Metadata
- Authors
- Vermeire, S., Van Assche, G., & Rutgeerts, P.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Vermeire, Séverine
- ORCID
- Vermeire, Séverine
- Venue
- Nature Clinical Practice Gastroenterology & Hepatology
- Published
- 2005-12
- Volume
- 2
- Issue
- 12
- Pages
- 580-586
- ISSN
- 1743-4378 (ISSN-L)
- 1743-4386
- OpenAlex
- W2036630215
- Cited by
- 149
- References
- 51
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 8 · 2020: 8 · 2019: 9 · 2018: 10 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 9 · 2013: 9 · 2012: 6
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Clinical Practice Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Keywords
- C-reactive protein, inflammatory markers, gastrointestinal inflammation, Crohn's disease, ulcerative colitis, acute pancreatitis, disease activity monitoring, colorectal cancer risk, anti-TNF therapy, acute phase response, interleukin-6, TNF-α
- MeSH terms
- C-Reactive Protein, Gastrointestinal Diseases, Humans, Inflammation, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.